We interrogated the CARIS Molecular Intelligence® database and identified 68 cases of chordoma and review of immunohistochemistry (IHC) biomarker results (Table 1) revealed eight-four percent of these chordoma samples had loss of TS expression suggesting that these tumors may respond to anti-folate drugs. This evidence concerns the gene TYMS and chordoma.